Related Information
New Protease Compound Could Lead To Better HIV Drugs
Researchers at the University of Michigan have developed a new compound that could mean a better Protease Inhibitor. Currently available protease inhibitors work by binding to the center of protease molecules, "freezing" them closed like a door, making it impossible for the protease stage of the HIV life cycle to continue, thus halting HIV replication. The new protease inhibitor compound halts the protease stage as well but by "freezing" the protease molecules open, like a a door jam, again making it impossible for the protease stage to continue. The benefit of this new compound is that the molecules are much smaller than traditional protease inhibitors meaning the med could be taken less often and could be absorbed by the body better. Studies of this compound are in a very early stage and will not yield a new drug for years.
